

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated statement of Financial status**  
as of 30 of September 2021

	30.09.2021	31.12.2020
	<i>BGN'000</i>	<i>BGN'000</i>
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	37 016	37 123
Intangible assets	3 837	3 816
Assets with usable assets	84	210
Trade receivables	5 157	5 157
<b>Total non-current assets</b>	<b>46 094</b>	<b>46 306</b>
<b>Current assets</b>		
Inventories	9 651	10 842
Trade and other receivables	62 357	60 084
Current corporate income tax	-	14
Treasury shares redeemed	-	1
Cash and cash equivalents	55	64
<b>Total current assets</b>	<b>72 063</b>	<b>71 005</b>
<b>Total assets</b>	<b>118 157</b>	<b>117 311</b>
<b>LIABILITIES</b>		
<b>Equity</b>		
Share capital	84 500	82 200
Reserves	12 094	12 032
Retained earnings	4 059	2 904
<b>Total</b>	<b>100 653</b>	<b>97 136</b>
<b>Non-current liabilities</b>		
Long-term loans	1 921	1 731
Deferred tax liabilities	1 139	1 139
Retirement benefit obligations	194	194
<b>Total non-current liabilities</b>	<b>3 254</b>	<b>3 064</b>
<b>Current liabilities</b>		
Trade and other liabilities	3 989	6 583
Short-term loans	9 782	9 783
Current portion of long-term loans	363	541
Current corporate income tax		
Other tax liabilities	116	204
<b>Total current liabilities</b>	<b>14 250</b>	<b>17 111</b>
<b>Total liabilities</b>	<b>17 504</b>	<b>20 175</b>
<b>Total equity and liabilities</b>	<b>118 157</b>	<b>117 311</b>

Date of preparation: 25.11.2021

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....


/B. Georgiev/

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated statement of comprehensive income**  
**as of 30 of September 2021**

	<b>30.09.2021</b>
	<i>BGN'000</i>
Revenue	34 901
Other income	22
<b>Total income</b>	<b>34 923</b>
Carrying amount of goods sold	(912)
Changes in inventories of finished products and work in progress	135
Materials and services	(22 975)
Personnel expenses	(4 059)
Depreciation / amortisation expenses	(2 960)
Other expenses	(360)
Finance income	14
Finance costs	(289)
<b>Total expenses</b>	<b>(31 226)</b>
<b>Profit before taxation</b>	<b>3 697</b>
Corporate income tax expense	(180)
<b>Profit/Loss for the period</b>	<b>3 517</b>
<b>Total comprehensive income for the period</b>	<b>3 517</b>
Earnings per share / in BGN per 1 share /	0.04

Date of preparation: 25.11.2021

Sofia

Prepared by:  / P. Moneva /

Executive Director:  /B. Georgiev/

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated cash flow statement**  
**as of 30 of September 2021**

**30.09.2021**

*BGN'000*

**Cash flows from operating activities**

Proceeds from sale of finished products, goods and services	25 470
Payments to suppliers of materials, goods and services	(17 452)
Payments to personnel	(3 797)
Payments of interest and dividends	(166)
Other proceeds / payments	(2 471)

<i>Net cash flows</i>	<b>1 584</b>
-----------------------	--------------

**Cash flows from investing activities**

Payments on non-current assets acquired	(1 093)
---	---------

<i>Net cash flows</i>	<b>(1 093)</b>
-----------------------	----------------

**Cash flows from financial activities**

Proceeds from loans	131
Payments on loans	(283)
Payment of interest, dividends	(20)
Payments on finance lease	(328)

<i>Net cash flows</i>	<b>(500)</b>
-----------------------	--------------

<b>Change in cash and cash equivalents</b>	<b>(9)</b>
--	------------

Cash and cash equivalents at the beginning of the period	<b>64</b>
--	-----------

Cash and cash equivalents at the end of the period	<b>55</b>
--	-----------

Date of preparation: 25.11.2021

Sofia

Prepared by:.....

/ P. Moneva /

Executive  
Director:.....

/B. Georgiev /

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated statement on changes in equity**  
**as of 30 of September 2021**

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
<b>Balance as of 01.01.2020</b>	<b>82 200</b>	<b>4 099</b>	<b>7 676</b>	<b>2 568</b>	<b>96 543</b>
Profit/loss for the period				604	604
Other comprehensive income		(11)			(11)
Including from tax effect of the revaluation of property, plant and equipment					
<b>Total comprehensive income</b>		<b>(11)</b>		<b>604</b>	<b>593</b>
Issue of shares by the owners					
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			268	(268)	
<b>Total amount of income and expenses recognised during the period</b>			<b>268</b>	<b>(268)</b>	
<b>Balance as of 31.12.2020</b>	<b>82 200</b>	<b>4 088</b>	<b>7 944</b>	<b>2 904</b>	<b>97 136</b>
<b>Balance as of 01.01.2021</b>	<b>82 200</b>	<b>4 088</b>	<b>7 944</b>	<b>2 904</b>	<b>97 136</b>
Profit/loss for the period				3 517	3 517
Other comprehensive income					
<b>Total comprehensive income</b>				<b>3 517</b>	<b>3 517</b>
Issue of shares by the owners	2 300			(2 300)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			62	(62)	
<b>Total amount of income and expenses recognised during the period</b>				<b>(62)</b>	
<b>Balance as of 30.09.2021</b>	<b>84 500</b>	<b>4 088</b>	<b>8 006</b>	<b>4 059</b>	<b>100 653</b>

Date of preparation: 25.11.2021  
Sofia

Prepared by:.....

/P. Moneva/

Executive Director:.....

/B. Georgiev /